Skip to main content
PMC home page
Virologica Sinica logoLink to Virologica Sinica
. 2011 Apr 7;26(2):81–94. doi: 10.1007/s12250-011-3183-z

PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV

Wei-wei Gai 1,2, Yan Zhang 1, Di-han Zhou 1, Yao-qing Chen 2, Jing-yi Yang, Hui-min Yan 1,2,✉
PMCID: PMC7091335  PMID: 21468931

Abstract

Severe Acute Respiratory Syndrome (SARS) is a deadly infectious disease caused by SARS Coronavirus (SARS-CoV). Inactivated SARS-CoV has been explored as a vaccine against SARS-CoV. However, safe and potent adjuvants, especially with more efficient and economical needle-free vaccination are always needed more urgently in a pandemic. The development of a safe and effective mucosal adjuvant and vaccine for prevention of emergent infectious diseases such as SARS will be an important advancement. PIKA, a stabilized derivative of Poly (I:C), was previously reported to be safe and potent as adjuvant in mouse models. In the present study, we demonstrated that the intraperitoneal and intranasal co-administration of inactivated SARS-CoV vaccine together with this improved Poly (I:C) derivative induced strong anti-SARS-CoV mucosal and systemic humoral immune responses with neutralizing activity against pseudotyped virus. Although intraperitoneal immunization of inactivated SARS-CoV vaccine alone could induce a certain level of neutralizing activity in serum as well as in mucosal sites, co-administration of inactivated SARS-CoV vaccine with PIKA as adjuvant could induce a much higher neutralizing activity. When intranasal immunization was used, PIKA was obligatorily for inducing neutralizing activity in serum as well as in mucosal sites and was correlated with both mucosal IgA and mucosal IgG response. Overall, PIKA could be a good mucosal adjuvant candidate for inactivated SARS-CoV vaccine for use in possible future pandemic.

Key words: SARS Coronavirus (SARS-CoV), Immune responses, Adjuvant, PIKA

Footnotes

Foundation items: National Natural Science Foundation of China (30670097); National Basic Research Program of China (973 Program) (2005CB522903); National Key R&D Program (2007BAI28B04); National S&T Major Project on Major Infectious Diseases (2008ZX10001-010).

References

  • 1.Alexopoulou L., Holt A. C., Medzhitov R., et al. Recognition of double-stranded rna and activation of nf-kappab by toll-like receptor 3. Nature. 2001;413(6857):732–738. doi: 10.1038/35099560. [DOI] [PubMed] [Google Scholar]
  • 2.Baer G. M. The effect of interferon on rabies infection of animals. Tex Rep Biol Med. 1981;41:526–531. [PubMed] [Google Scholar]
  • 3.Belshe R. B., Mendelman P. M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998;338(20):1405–1412. doi: 10.1056/NEJM199805143382002. [DOI] [PubMed] [Google Scholar]
  • 4.Bradney C. P., Sempowski G. D., Liao H. X., et al. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin g (igg) and iga antibodies in serum and mucosal secretions after nasal immunization. J Virol. 2002;76(2):517–524. doi: 10.1128/JVI.76.2.517-524.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Burns J. W., Siadat-Pajouh M., Krishnaney A. A., et al. Protective effect of rotavirus vp6-specific iga monoclonal antibodies that lack neutralizing activity. Science. 1996;272(5258):104–107. doi: 10.1126/science.272.5258.104. [DOI] [PubMed] [Google Scholar]
  • 6.Champney K. J., Levine D. P., Levy H. B., et al. Modified polyriboinosinic-polyribocytidylic acid complex: Sustained interferonemia and its physiological associates in humans. Infect Immun. 1979;25(3):831–837. doi: 10.1128/iai.25.3.831-837.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Czerkinsky C., Anjuere F., Mcghee J. R., et al. Mucosal immunity and tolerance: Relevance to vaccine development. Immunol Rev. 1999;170:197–222. doi: 10.1111/j.1600-065X.1999.tb01339.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Fouchier R. A., Kuiken T., Schutten M., et al. Aetiology: Koch’s postulates fulfilled for sars virus. Nature. 2003;423(6937):240. doi: 10.1038/423240a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gai W., Zou W., Lei L., et al. Effects of different immunization protocols and adjuvant on antibody responses to inactivated sars-cov vaccine. Viral Immunol. 2008;21(1):27–37. doi: 10.1089/vim.2007.0079. [DOI] [PubMed] [Google Scholar]
  • 10.Herman R., Baron S. Immunologic-mediated protection of trypanosoma congolense-infected mice by polyribonucleotides. J Protozool. 1971;18(4):661–666. doi: 10.1111/j.1550-7408.1971.tb03393.x. [DOI] [PubMed] [Google Scholar]
  • 11.Ichinohe T., Watanabe I., Ito S., et al. Synthetic double-stranded rna poly(i:C) combined with mucosal vaccine protects against influenza virus infection. J Virol. 2005;79(5):2910–2919. doi: 10.1128/JVI.79.5.2910-2919.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Jacobs B. L., Langland J. O. When two strands are better than one: The mediators and modulators of the cellular responses to double-stranded rna. Virology. 1996;219(2):339–349. doi: 10.1006/viro.1996.0259. [DOI] [PubMed] [Google Scholar]
  • 13.Kang S. M., Compans R. W. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol. 2003;77(6):3615–3623. doi: 10.1128/JVI.77.6.3615-3623.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Kapikian A. Z., Hoshino Y., Chanock R. M., et al. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis. 1996;174(Suppl1):S65–72. doi: 10.1093/infdis/174.Supplement_1.S65. [DOI] [PubMed] [Google Scholar]
  • 15.Koutsky L. A., Ault K. A., Wheeler C. M., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645–1651. doi: 10.1056/NEJMoa020586. [DOI] [PubMed] [Google Scholar]
  • 16.Kumar M., Carmichael G. G. Antisense rna: Function and fate of duplex rna in cells of higher eukaryotes. Microbiol Mol Biol Rev. 1998;62(4):1415–1434. doi: 10.1128/mmbr.62.4.1415-1434.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lamm M. E. Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol. 1997;51:311–340. doi: 10.1146/annurev.micro.51.1.311. [DOI] [PubMed] [Google Scholar]
  • 18.Lau Y. F., Tang L. H., Ooi E. E. A tlr3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine. 2009;27(9):1354–1364. doi: 10.1016/j.vaccine.2008.12.048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lau Y F, Tang L H, Mccall A W, et al. An adjuvant for the induction of potent, protective humoral responses to an h5n1 influenza virus vaccine with antigen-sparing effect in mice. J Virol, 84(17): 8639–8649. [DOI] [PMC free article] [PubMed]
  • 20.Lau Y. L., Peiris J. S. Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol. 2005;17(4):404–410. doi: 10.1016/j.coi.2005.05.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Leung W. K., To K. F., Chan P. K., et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125(4):1011–1017. doi: 10.1016/j.gastro.2003.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Levine M. M. Immunization against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr. 2000;31(4):336–355. doi: 10.1097/00005176-200010000-00003. [DOI] [PubMed] [Google Scholar]
  • 23.Li L., Shen E.-X., Huang J., et al. Pika adjuvant induces the immune responses in mouse in vitro and in vivo. Chin J Immunol. 2006;22(11):983–986. [Google Scholar]
  • 24.Li P.-P., Yang X.-M., Fang Z.-Z., et al. Preparation of inactivated sars vaccine. Chin J Biologicals. 2005;18:390–393. [Google Scholar]
  • 25.Lin H. X., Gontier C., Saron M., et al. A new immunostimulatory complex (pickca) in experimental rabies: Antiviral and adjuvant effects. Arch Virol. 1993;131(3–4):307–319. doi: 10.1007/BF01378634. [DOI] [PubMed] [Google Scholar]
  • 26.Lin M., Tseng H.-K., Trejaut J.-A., et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet. 2003;4:9. doi: 10.1186/1471-2350-4-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Luo J., Gai W., Lei L., et al. Prokaryotic expression of the sars-cov spike protein and preliminary studies on its mucosal immune response. J Wuhan Univ (Natural Science) 2006;52(6):733–738. [Google Scholar]
  • 28.Mazanec M. B., Kaetzel C. S., Lamm M. E., et al. Intracellular neutralization of virus by immunoglobulin a antibodies. Proc Natl Acad Sci USA. 1992;89(15):6901–6905. doi: 10.1073/pnas.89.15.6901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Modlin J. F. Poliomyelitis in the united states: The final chapter? JAMA. 2004;292(14):1749–1751. doi: 10.1001/jama.292.14.1749. [DOI] [PubMed] [Google Scholar]
  • 30.Neutra M. R., Kozlowski P. A. Mucosal vaccines: The promise and the challenge. Nat Rev Immunol. 2006;6(2):148–158. doi: 10.1038/nri1777. [DOI] [PubMed] [Google Scholar]
  • 31.Qu X. X., Hao P., Song X. J., et al. Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. J Biol Chem. 2005;280(33):29588–29595. doi: 10.1074/jbc.M500662200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sambrook J F E, Maniatis T. 1989. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press.
  • 33.Shen E., Li L., Li L., et al. Pika as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with hbsag plus pika. Cell Mol Immunol. 2007;4(2):113–120. [PubMed] [Google Scholar]
  • 34.Sloat B. R., Cui Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res. 2006;23(6):1217–1226. doi: 10.1007/s11095-006-0206-9. [DOI] [PubMed] [Google Scholar]
  • 35.Subbarao K., Mcauliffe J., Vogel L., et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol. 2004;78(7):3572–3577. doi: 10.1128/JVI.78.7.3572-3577.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Takao S. I., Kiyotani K., Sakaguchi T., et al. Protection of mice from respiratory sendai virus infections by recombinant vaccinia viruses. J Virol. 1997;71(1):832–838. doi: 10.1128/jvi.71.1.832-838.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Takasuka N., Fujii H., Takahashi Y., et al. A subcutaneously injected uv-inactivated sars coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004;16(10):1423–1430. doi: 10.1093/intimm/dxh143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Tang J. W., To K. F., Lo A. W., et al. Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (sars-cov) in postmortem tissues. J Med Virol. 2007;79(9):1245–1253. doi: 10.1002/jmv.20873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Ter Meulen J., Bakker A. B., Van Den Brink E. N., et al. Human monoclonal antibody as prophylaxis for sars coronavirus infection in ferrets. Lancet. 2004;363(9427):2139–2141. doi: 10.1016/S0140-6736(04)16506-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.To K. F., Lo A. W. Exploring the pathogenesis of severe acute respiratory syndrome (sars): The tissue distribution of the coronavirus (sars-cov) and its putative receptor, angiotensin-converting enzyme 2 (ace2) J Pathol. 2004;203(3):740–743. doi: 10.1002/path.1597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Underdown B. J., et al. Parenteral immunization induces mucosal protection: A challenge to the mucosal immunity paradigm. In: Mestecky J., Bienenstock J., Lamm M. E., et al., editors. Mucosal immunology. 3rd edition. Burlington: Elsevier Academic Press; 2005. pp. 831–840. [Google Scholar]
  • 42.Verdijk R. M., Mutis T., Esendam B., et al. Polyriboinosinic polyribocytidylic acid (poly(i:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163(1):57–61. [PubMed] [Google Scholar]
  • 43.Xiao B. G., Link H. Mucosal tolerance: A twoedged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol. 1997;85(2):119–128. doi: 10.1006/clin.1997.4432. [DOI] [PubMed] [Google Scholar]
  • 44.Yan H., Lamm M. E., Bjorling E., et al. Multiple functions of immunoglobulin a in mucosal defense against viruses: An in vitro measles virus model. J Virol. 2002;76(21):10972–10979. doi: 10.1128/JVI.76.21.10972-10979.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Yang Y. L., Reis L. F., Pavlovic J., et al. Deficient signaling in mice devoid of double-stranded rnadependent protein kinase. Embo J. 1995;14(24):6095–6106. doi: 10.1002/j.1460-2075.1995.tb00300.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Wuhan Institute of Virology, Chinese Academy of Sciences

RESOURCES